SkyePharma faces regulatory delay for lead drug

Shares of SkyePharma were sliding this morning after the UK developer told investors that the FDA would probably come back with a request for more data on its lead drug Flutiform, adding to the time it will take to reach the marketplace.

SkyePharma based its prediction on an analysis of its 74-day letter from the FDA, concluding that more clinical work would probably be needed before the agency approves the asthma drug. Analysts appeared concerned, but not overly alarmed.

"Potentially it is significant because there might be more data needed, but it's not significant enough for me to start reviewing my financial model at this point," analyst Jacob Plieth at Edison Investment Research tells Reuters.

- here's the report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.